Novo Nordisk gains US FDA green light for its oral semaglutide
Novo Nordisk (NOV: N) late Friday day announced the much awaited US Food and Drug Administration approval of its first-of-a-kind oral diabetes drug Rybelsus (semaglutide), as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, with the news sending the Danish diabetes giant’s shares up 2.59% to 350.50 Danish kroner in late trading.
Rybelsus, the brand name for oral semaglutide in the USA, is the first approved glucagon-like peptide-1 (GLP-1) receptor agonist in a tablet. The approval of Rybelsus is based on the results from 10 PIONEER clinical trials which included 9,543 adults with type 2 diabetes. Rybelsus more effectively lowered blood sugar than sitagliptin and empagliflozin. Furthermore, treatment with Rybelsus resulted in up to 4.4kg reduction in body weight.
Blockbuster sales forecast
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze